Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9258071rdf:typepubmed:Citationlld:pubmed
pubmed-article:9258071lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C1332717lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C1706438lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C0278678lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C0079722lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C0027695lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C0085358lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C0677930lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C1413244lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C2698600lld:lifeskim
pubmed-article:9258071lifeskim:mentionsumls-concept:C1707391lld:lifeskim
pubmed-article:9258071pubmed:issue3 Pt 1lld:pubmed
pubmed-article:9258071pubmed:dateCreated1997-9-16lld:pubmed
pubmed-article:9258071pubmed:abstractTextMetastatic renal cell carcinoma is a disease with a mean survival of 6 to 10 months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell carcinoma, is associated with a 14% response rate and durable remissions in some patients with high performance status. We performed a series of trials of IL-2 plus tumor infiltrating lymphocyte cell therapy and report the clinical results from 62 patients enrolled in these trials.lld:pubmed
pubmed-article:9258071pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9258071pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9258071pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9258071pubmed:languageenglld:pubmed
pubmed-article:9258071pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9258071pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9258071pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9258071pubmed:statusMEDLINElld:pubmed
pubmed-article:9258071pubmed:monthSeplld:pubmed
pubmed-article:9258071pubmed:issn0022-5347lld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:deKernionJJlld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:BelldegrunAAlld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:FiglinR ARAlld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:MoldawerNNlld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:TsoC LCLlld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:KabooRRlld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:PierceW CWClld:pubmed
pubmed-article:9258071pubmed:authorpubmed-author:GitlitzBBlld:pubmed
pubmed-article:9258071pubmed:issnTypePrintlld:pubmed
pubmed-article:9258071pubmed:volume158lld:pubmed
pubmed-article:9258071pubmed:ownerNLMlld:pubmed
pubmed-article:9258071pubmed:authorsCompleteYlld:pubmed
pubmed-article:9258071pubmed:pagination740-5lld:pubmed
pubmed-article:9258071pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:meshHeadingpubmed-meshheading:9258071-...lld:pubmed
pubmed-article:9258071pubmed:year1997lld:pubmed
pubmed-article:9258071pubmed:articleTitleTreatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.lld:pubmed
pubmed-article:9258071pubmed:affiliationDepartment of Medicine, UCLA School of Medicine, Johnson Comprehensive Cancer Center, Los Angeles, California 90095-7059, USA.lld:pubmed
pubmed-article:9258071pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9258071pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9258071pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9258071pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9258071lld:pubmed